First Tracks Biotherapeutics CMO reports 16,667 PSUs
First Tracks Biotherapeutics, Inc. has updated insider ownership information for Chief Medical Officer Paul F. Lizzul, reflecting his holding of 16,667 performance stock units (PSUs).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
First Tracks Biotherapeutics, Inc. has updated insider ownership information for Chief Medical Officer Paul F. Lizzul, reflecting his holding of 16,667 performance stock units (PSUs). These PSUs relate to common stock and vest in two equal 50% tranches on March 12, 2027 and March 12, 2028, subject to his continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Performance Stock Unit F1 | -- | -- | -- |
Footnotes (1)
- F1. The PSUs vest and settle over two years; 50% vests on March 12, 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Key Figures
Key Terms
Performance Stock Unit financial
underlying security title financial
vest and settle financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does First Tracks Biotherapeutics (TRAX) disclose in this Form 3/A amendment?
How many performance stock units does the TRAX Chief Medical Officer hold?
What is the vesting schedule for the 16,667 PSUs reported by TRAX?
How are the reported TRAX performance stock units linked to common stock?
AI-generated analysis. How Rhea-AI works. Not financial advice.